THE SITUATION OF SCLERODERMA RENAL CRISIS IN PATIENTS WITH DIFFUSE SCLERODERMA AT BACH MAI HOSPITAL

Phạm Hùng Lê, Thị Liễu Lê

Main Article Content

Abstract

Objectives: Describe clinical and subclinical characteristics of scleroderma renal crisis (SRC) in patients with diffuse scleroderma and examinate some risk factors of SRC. Subjects and methods: 25 patients with diffuse scleroderma (diagnosed by Classification of ACR/EULAR 2013) and symptoms of SRC (according to ISRCS standard, excluded acute kidney injury by other causes), hospitalised at Bach Mai hospital between 2016 and 2023 are included in this study. Results: Incidence rate of SRC is 8%. Mean age when SRC onset is 60,4 ± 11,8 years old. SRC occurs in a mean 2,3 years after systemic scleroderma (SSc) was diagnosed. 58 percent of SRC patients have duration of SSc less than 1 year. 88% patients have hypertension; mean blood pressure is approximately 162 mmHg. Oedema and rising serum creatinin occur in all patients; mean serum creatinin is 466,3 ± 177,5 µmol/L. Proteinuria and hematuria are noted in almost cases (over 88%). Mortality rate is up to 64% in 6 months. There are significant differences between two groups (SRC and no-SRC, p < 0,05) about rate of anemia, pulmonary hypertension, heart failure, age over 58 years old, duration of systemic scleroderma less than 4 years, methyl-prednisolon dose over 16 mg per day, thrombocytopenia and hypertension. Conclusion: Scleroderma Renal Crisis is characterized by acute kidney injury and maglinant hypertension; it has poor outcome and high mortality rate. Risk factors have been shown in this study include anemia, pulmonary hypertension, heart failure, age over 58 years old, duration of systemic scleroderma less than 4 years, methyl-prednisolon dose over 16 mg per day, thrombocytopenia and hypertension. Thrombocytopenia is one of the risk factors of poor outcome (p = 0,021).

Article Details

References

1. Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12(11): 678-691. doi: 10.1038/ nrneph.2016.124
2. Vaidya PN, Basyal B, Finnigan NA. Scleroderma And Renal Crisis. In: StatPearls. StatPearls Publishing; 2021. Accessed June 19, 2021. http://www.ncbi.nlm.nih.gov/books/NBK482424
3. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25-YEAR EXPERIENCE WITH 68 CASES. Medicine (Baltimore). 1983;62(6):335-352.
4. Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatol Oxf Engl. 2012;51(3):460-467. doi:10.1093/rheumatology/ker271
5. Tài liệu y học – Trung tâm Tích hợp dữ liệu – Cục Công nghệ thông tin – Bộ Y tế. Accessed June 19, 2021. http://tailieu.yte.gov.vn/ chi-tiet-tai-lieu/gop-phan-nghien-cuu-dac-diem-lam-sang-va-can-lam-sang-cua-ton-thuong-than-trong-xo-cung-bi-he-thong-tien-trien
6. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983;62(6):3 35-352. doi:10.1097/ 00005792-198311000-00001
7. Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113(5):352-357. doi:10.7326/0003-4819-113-5-352
8. Walker JG, Ahern MJ, Smith MD, et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J. 2003; 33(5-6): 216-220. doi:10.1046/ j.1445-5994. 2003.00358.x
9. Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatol Oxf Engl. 2012;51(3):460-467. doi:10.1093/rheumatology/ker271
10. DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002;46(11):2983-2989. doi:10.1002/art.10589